Elizabeth Holmes, former CEO of Theranos, remains influential in tech, advising Haemanthus from prison. Haemanthus, led by Billy Evans, aims to innovate medical testing using AI and Raman spectroscopy. Evans…
The closure of a key CDC laboratory, initiated by the Trump administration, disrupts STI surveillance and the fight against drug-resistant strains, especially "super gonorrhea." The Gonococcal Isolate Surveillance Project (GISP),…
A surge in online search activity highlights growing investor interest in biotech companies. Biotie Therapies is at the forefront, focusing on transformative treatments for central nervous system disorders such as…
The biotech industry offers high-risk, high-reward opportunities with the potential for groundbreaking innovations that can transform healthcare. Investors are drawn to nimble startups with promising pipelines, innovative technologies, and strong…
Wacker Biotech and RNAV8 Bio have partnered to advance mRNA therapeutics, aiming to revolutionize treatment landscapes for various diseases. Wacker Biotech specializes in microbial fermentation, producing high-quality pharmaceutical proteins and…
The biotech and pharmaceutical industries are undergoing strategic realignments, leading to layoffs as companies refocus on core objectives. Nkarta and Atea Pharmaceuticals have significantly reduced their workforce, emphasizing key therapeutic…
The resignation of FDA vaccine official Peter Marks has unsettled the U.S. biotechnology sector, provoking investor anxiety and a significant stock downturn. The S&P 500 biotechnology ETF plunged by 4.9%,…
Ultragenyx Pharmaceutical Inc. is recognized for its pioneering work in therapies for rare genetic diseases, distinguishing itself in the biotech industry. The company's portfolio includes important drugs such as Crysvita,…
The biotech industry is leading healthcare innovation with transformative therapies for complex diseases. Xenon Pharmaceuticals is close to approval for a new epilepsy treatment in Phase 3 trials. Karuna Therapeutics'…
UNITY Biotechnology is set to present promising results from their Phase 2b ASPIRE study on March 24, 2025, with potential breakthroughs in treating Diabetic Macular Edema (DME). The innovative compound…